Page last updated: 2024-11-05

talactoferrin alfa and Cross Infection

talactoferrin alfa has been researched along with Cross Infection in 1 studies

talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006

Cross Infection: Any infection which a patient contracts in a health-care institution.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sherman, MP1
Adamkin, DH1
Niklas, V1
Radmacher, P1
Sherman, J1
Wertheimer, F1
Petrak, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants[NCT00854633]Phase 1/Phase 2120 participants (Anticipated)Interventional2009-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for talactoferrin alfa and Cross Infection

ArticleYear
Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants.
    The Journal of pediatrics, 2016, Volume: 175

    Topics: Administration, Oral; Bacteremia; Cross Infection; Double-Blind Method; Enterocolitis, Necrotizing;

2016